Mr. Kubik has over 25 years of experience in business development, alliance and portfolio management and drug discovery and development. The bulk of this work has focused around successfully leading transformative deal creation and productive alliances in the biologics and therapeutic monoclonal antibody (mAb) areas.
Most recently, Mark served as CBO at AvantGen, where he headed its business development function and was responsible for securing multiple mAb discovery and development partnerships and providing strategic guidance. Prior to AvantGen, Mark held positions in business development and led transformative and award-winning deal making at Abgenix (now Amgen), Protein Design Labs (PDL), XOMA, Seattle Genetics (now Seagen), MacroGenics, Glenmark Pharmaceuticals, i2 Pharmaceuticals / Velocity Sciences, and Invenra, among others.
Deal highlights for Mark, include a global co-development agreement on behalf of Abgenix (now Amgen) with Immunex for Vectibix® (panitumumab), an ex-US strategic alliance on behalf of Seattle Genetics with Takeda for Adcetris® (brentuximab vedotin) (nominated by Recombinant Capital / Allicense for consideration as 2009 “Alliance of the Year”) and a multi-program bispecific mAb discovery collaboration on behalf of MacroGenics with Gilead (won Licensing Executives Society (LES) Alliance of the Year in Life Sciences Award in 2013).
Mark received his MBA in Finance from the Leeds School of Business at the University of Colorado-Boulder and his BA (cum laude) in Molecular, Cellular and Developmental Biology (MCDB) from CU-Boulder.